You might also like
Glaukos Corporation (GKOS) is an ophthalmic pharmaceutical and medical technology company specializing in innovative therapies for chronic eye diseases, including glaucoma, corneal disorders, and retinal diseases. The company develops and commercializes advanced medical devices and pharmaceutical therapies designed to improve patient outcomes and disrupt traditional treatment paradigms. Its offerings include minimally invasive surgical devices, bio-activated pharmaceutical therapies, and cutting-edge drug delivery systems.
- Glaucoma - Develops and markets Micro-Invasive Glaucoma Surgery (MIGS) devices and pharmaceutical therapies, including the iDose TR, which delivers sustained intraocular pressure reduction for glaucoma and ocular hypertension patients.
- Corneal Health - Provides bio-activated pharmaceutical therapies for corneal disorders, such as keratoconus, and is advancing treatments for dry eye and refractive vision correction.
- Retinal Diseases - Focuses on developing therapies for retinal conditions, including neovascular age-related macular degeneration, diabetic macular edema, and retinal vein occlusion.
| Name | Position | External Roles | Short Bio | |
|---|---|---|---|---|
Thomas W. Burns ExecutiveBoard | Chairman of the Board and CEO | Board Member at Pulmonx Corporation (NASDAQ: LUNG) | Thomas W. Burns has been a director at Glaukos since 2002 and CEO since then. He became Chairman of the Board in 2021. He has a proven record of building successful medical device and pharmaceutical businesses. | View Report → |
Alex R. Thurman Executive | Senior Vice President & CFO | None | Alex R. Thurman joined Glaukos in July 2016 as VP, Global Tax and Administration. He became Senior VP & CFO in April 2022. He played a key role in building Glaukos' finance organization and SOX compliance. | |
Joseph E. Gilliam Executive | President and COO | Board Member at Caris Life Sciences | Joseph E. Gilliam joined Glaukos in May 2017 as CFO and Senior VP, Corporate Development. He was promoted to President and COO in April 2022. He played a pivotal role in leading Glaukos' IPO while at JPMorgan. | |
Tomas Navratil Executive | Chief Development Officer | None | Tomas Navratil joined Glaukos in October 2020 as Senior VP, R&D, and became CDO in April 2022. He has nearly 20 years of experience in ophthalmic drug and medical device R&D and regulatory affairs. | |
Aimee S. Weisner Board | Independent Director | Independent Director at Lensar, Inc. and STAAR Surgical Company | Aimee S. Weisner has been an Independent Director since 2014. She has extensive legal and compliance experience in the medical device and pharmaceutical industries. | |
David F. Hoffmeister Board | Independent Director | Director at Celanese Corporation, ICU Medical, Inc., StepStone Group, Inc., and Kaiser Permanente | David F. Hoffmeister has been an Independent Director since 2014. He has a strong finance background and extensive public company board experience. | |
Denice M. Torres Board | Independent Director | CEO of The Ignited Company, Board Member at Karuna Therapeutics, Surface Oncology, 2seventybio, National Resilience, and Thirty Madison | Denice M. Torres has been a Board Member since March 2021. She is the CEO of The Ignited Company and holds multiple board positions in the biotech sector. | |
Gilbert H. Kliman, MD Board | Independent Director | Independent Director at STAAR Surgical Company and Director at ORBIS International | Gilbert H. Kliman, M.D., has been an Independent Director since 2007. He is a practicing ophthalmologist with significant expertise in financial markets and board experience. | |
Marc A. Stapley Board | Independent Director | CEO and Board Member at Veracyte, Inc., Board Member at Helix Opco LLC, and Premier Foods, Inc. | Marc A. Stapley has been an Independent Director since 2014. He has held various executive roles in the biotech industry, including CEO of Veracyte. | |
Mark J. Foley Board | Lead Independent Director | CEO and Board Member at Revance Therapeutics, Inc. (Nasdaq: RVNC) | Mark J. Foley has been an Independent Director since 2014 and Lead Independent Director since December 2021. He serves as Chair of the CNG Committee and engages with top stockholders on governance matters. |
-
With the expected slowdown to high single-digit growth in your international glaucoma business due to FX headwinds and competition from new product launches by competitors like Alcon in key markets such as Japan and France, how does the company plan to mitigate these challenges and sustain international growth momentum?
-
Given that the non-iDose revenues in your U.S. glaucoma business are projected to be flat or even decline due to LCD headwinds and the expiration of the Hydrus royalty, what specific strategies are you implementing to revitalize growth in your core iStent franchise?
-
Considering the historical challenges with patient access and reimbursement for Photrexa, how are you addressing potential obstacles with the upcoming launch of Epioxa to ensure a smoother commercialization and better patient access?
-
In light of the reimbursement complexities for iDose TR, especially regarding professional fee schedules and MAC coverage, what is your timeline and strategy for achieving consistent reimbursement confidence among providers, and how might any delays impact your 2025 iDose TR growth expectations?
-
With dependencies on regulatory approvals like the MDR approval for iStent Infinite in Europe and potential competitive pressures, how are you adjusting your forecasts and investment priorities to account for these uncertainties in your pipeline and international expansion plans?
Competitors mentioned in the company's latest 10K filing.
| Company | Description |
|---|---|
PeschkeTrade GmBH | Globally competes against numerous providers of corneal crosslinking therapies, particularly in the area of corneal disorders. |
A large company that competes in multiple areas, including corneal disorder therapies, retinal health pipeline, and procedural pharmaceutical products for glaucoma. | |
Competes in the corneal disorder space and acquired Ivantis Inc. in January 2022, making it a competitor in the MIGS (Micro-Invasive Glaucoma Surgery) offerings. | |
A large company competing in the corneal disorder space, particularly in areas like dry eye and refractive conditions. | |
A large pharmaceutical company that may compete with the retinal health pipeline if approved. | |
Genentech/Roche | A significant competitor in the retinal health pipeline space. |
A large pharmaceutical company competing in the retinal health pipeline area. | |
Bayer | A competitor in the retinal health pipeline space. |
Sight Sciences | Competes in the MIGS offerings for glaucoma treatment. |
New World Medical | A competitor in the MIGS offerings for glaucoma treatment. |
Recent press releases and 8-K filings for GKOS.
Glaukos Presents Q4 2024 Investor Presentation
- Glaukos Corporation issued an 8-K investor presentation outlining its current strategic focus and forward-looking initiatives to drive innovation in ocular therapies, including sustained-release drug delivery and combination treatments.
- The presentation highlights robust clinical progress, notably positive Phase 3 outcomes for iDose TR, with a significant proportion of patients maintaining controlled intraocular pressure, emphasizing its potential as a key pipeline asset.
- The company detailed strategic milestones for 2025 across its product portfolio—including advancements in glaucoma, keratoconus, and retinal therapies—as well as plans to expand its trained surgeon network and secure regulatory milestones.